Relationship Between Plasma Pentraxin 3 Concentration and Platelet Indices in Patients With Stable Coronary Artery Disease

Abstract

Few reports have analyzed the effect of pentraxin 3 (PTX3) on platelets and their activation. We explored the association between plasma PTX3 and platelet indices. Forty-nine patients with stable coronary artery disease (CAD) were enrolled. Based on median PTX3, the study population was divided into group 1 (n = 25; PTX3 ≤ 0.98 ng/mL) and group 2 (n = 24; PTX3 > 0.98 ng/mL). Platelet indices investigated included mean platelet volume (MPV), platelet distribution width (PDW), platelets and large cell ratio (P-LCR), MPV to platelet count ratio (MPV/PC), platelet to lymphocyte ratio (PLR), and MPV to lymphocyte ratio (MPVLR). Patients with lower PTX3 had a higher lymphocyte count. Platelet count was similar in both groups. Notwithstanding, patients with higher PTX3 concentrations had elevated MPV (8.3 vs 10.0 fL; P < .001) and PDW (9.4 vs 12.4 fL; P < .001). However, the MPV/PC ratio was similar in both groups. Thromboinflammatory biomarkers (PLR, MPVLR) were also elevated in group 2. Pentraxin 3showed a strong, positive correlation with MPV (r = .75, P < .01) and PDW (r = .80, P < .01), and weak to moderate correlation with MPVLR. In conclusion, PTX3 is associated with larger platelet size as assessed by platelet volume indices. There is a strong correlation between plasma PTX3 level and MPV and PDW.

Keywords

pentraxin 3 platelet indices mean platelet volume platelet distribution width platelet to lymphocyte ratio mean platelet volume to lymphocyte ratio coronary artery disease

Get full access to this article

View all access options for this article.

References

Libby

Ridker

. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004;116(suppl 6A):9S–16S.

. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. Mediators Inflamm. 2013;2013:726178.

Nakou

Liberopoulos

Milionis

Elisaf

. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol. 2008;6(4):258–70.

Inoue

Sugiyama

Reid

. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007;27(1):161–7.

Latini

Maggioni

Peri

. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110(16):2349–54.

Matsui

Ishii

Kitagawa

. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis. 2010;210(1):220–5.

Dubin

Shlipak

Whooley

Peralta

. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J. 2012;163(2):274–9.

Hudzik

Danikiewicz

Szkodzinski

Polonski

Zubelewicz-Szkodzinska

. Pentraxin-3 concentrations in stable coronary artery disease depend on the clinical presentation. Eur Cytokine Netw. 2014;25(3):41–45.

Knoflach

Kiechl

Mantovani

. Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies. PLoS One. 2012;7(2):e31474.

10.

Abderrahim-Ferkoune

Bezy

Chiellini

. Characterization of the long pentraxin PTX3 as a TNFalpha-induced secreted protein of adipose cells. J Lipid Res. 2003;44(5):994–1000.

11.

Manfredi

Rovere-Querini

Bottazzi

Garlanda

Mantovani

. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol. 2008;20(5):538–44.

12.

Norata

Garlanda

Catapano

. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010;20(2):35–40.

13.

Fornai

Carrizzo

Forte

. The inflammatory protein Pentraxin 3 in cardiovascular disease. Immun Ageing. 2016;13(1):25.

14.

Vilahur

Badimon

. Biological actions of pentraxins. Vascul Pharmacol. 2015;73:38–44.

15.

Maugeri

Rovere-Querini

Slavich

. Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction. J Immunol. 2011;187(2):970–9.

16.

Santilli

Guagnano

Innocenti

. Pentraxin 3 and platelet activation in obese patients after gastric banding. Circ J. 2016;80(2):502–11.

17.

Michelson

. Methods for the measurement of platelet function. Am J Cardiol. 2009;103(3 suppl):20A–26A.

18.

Leader

Pereg

Lishner

. Are platelet volume indices of clinical use? A multidisciplinary review. Ann Med. 2012;44(8):805–16.

19.

Zaccardi

Rocca

Pitocco

Tanese

Rizzi

Ghirlanda

. Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis. Diabetes Metab Res Rev. 2015;31(4):402–10.

20.

Hudzik

Szkodzinski

Gorol

. Platelet-to-lymphocyte ratio is a marker of poor prognosis in patients with diabetes mellitus and ST-elevation myocardial infarction. Biomark Med. 2015;9(3):199–207.

21.

Hudzik

Szkodzinski

Lekston

Gierlotka

Polonski

Gasior

. Mean platelet volume-to-lymphocyte ratio: a novel marker of poor short- and long-term prognosis in patients with diabetes mellitus and acute myocardial infarction. J Diabetes Complications. 2016;30(6):1097–102.

22.

Proctor

Morrison

Talwar

. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633–41.

23.

Chu

Becker

Berger

. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(1):148–56.

24.

Deban

Russo

Sironi

. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010;11(4):328–34.

25.

Liu

Jiang

Yan

. Pentraxin 3 promotes oxLDL uptake and inhibits cholesterol efflux from macrophage-derived foam cells. Exp Mol Pathol. 2014;96(3):292–9.

26.

Rolph

Zimmer

Bottazzi

Garlanda

Mantovani

Hansson

. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22(5):e10–e14.

27.

Savchenko

Imamura

Ohashi

. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol. 2008;215(1):48–55.

28.

Bonacina

Barbieri

Cutuli

. Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation. Biochim Biophys Acta. 2016;1862(6):1182–90.

29.

Shindo

Tanemura

Yata

. Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability. PLoS One. 2014;9(6):e100045.

30.

Violi

Pastori

. Pentraxin 3—a link between obesity, inflammation and vascular disease? Circ J. 2016;80(2):327–8.